Revmatologie
- Address
- Táborská 325/57, 140 00 Prague, Czechia
Revmatologie - Rheumatology Research Center
Revmatologie is a specialized rheumatology research center dedicated to advancing treatment options for patients with autoimmune and inflammatory joint diseases. The center focuses on evaluating novel therapeutic approaches in early rheumatoid arthritis, particularly in treatment-naïve patient populations where early intervention can significantly impact disease progression and long-term outcomes.
- Phase II clinical trials evaluating innovative oral therapies for rheumatoid arthritis
- Combination therapy studies with methotrexate and novel disease-modifying agents
- Research in DMARD-naïve patients with active inflammatory disease
The center's research program emphasizes dose-response evaluation and safety profiles of emerging compounds in combination with standard disease-modifying anti-rheumatic drugs (DMARDs). Through rigorous randomized, double-blind, placebo-controlled trials, Revmatologie contributes valuable evidence for optimizing treatment strategies in newly diagnosed rheumatoid arthritis patients with active inflammation.
Site Overview
Activity Indicator
Last 6 months
Trial Flow
How this site's trials are distributed across therapeutic areas and active substances (IMPs), and how they're positioned within their overall lifecycle status. Flow thickness represents the number of unique trials.
Compounds & Molecules Timeline
The time span of clinical-trial activity for the main active substances (IMPs) studied at this site over the last 8 years. Each bar runs from the earliest trial start to the most recent end; a substance with a trial still open has no recorded end and is shown as ongoing.
Sponsor & Partnership
Top sponsors by active trials, and the ones that have come back for more than one study.
Sponsor Network
Top 10 by active trials.
No sponsors linked to active trials.
Partnership History
Sponsors with repeated collaboration (≥ 2 trials).
No repeated partnerships found.
Sponsor Network Graph
How sponsors and therapeutic areas connect across this site's active trials: each link is at least one active trial shared between them, and bigger nodes mean more activity. Click a node to see its exact connections.
Country Benchmark
Compared to 634 other sites in Czechia
Therapeutic Area Benchmark — Czechia
Select a therapeutic area to compare against other sites in Czechia.
Competitor Comparison
Similar sites in the same country running a comparable number of trials (within ±30%), scored on how closely their trial portfolios match this one. Higher percentages mean a more similar profile.
Country: Czechia
Market Share
Country: Czechia
Therapeutic Area Market Share
Select a therapeutic area to view its disease coverage breakdown.
Heat Maps & Advanced Analytics
How often specific conditions appear in trials across this site and comparable sites from the same country. Each row is a site, each column a condition, and each cell the number of trials on it — darker means more activity.
Other Trials in Revmatologie
| Trial | Sponsor | Phase | Status | Start Date | End Date |
|---|---|---|---|---|---|
| Efficacy and Safety Evaluation of Oral Resomelagon with Methotrexate in DMARD-Naïve Patients with Early Rheumatoid Arthritis: A Phase II Multicenter Study | Synact Pharma ApS | Phase II | Not Recruiting | Dec 2024 | May 2026 |
IMP list
lock Showing 1 of 2 compounds — the rest is available on a paid plan.
| IMP | Trials | Status | First start | Last start |
|---|---|---|---|---|
| Methotrexate | 1 | Unknown | 2024-12-05 | 2024-12-05 |
Request feasibility information
Ask this centre about capacity, equipment and patient population.
Upgrade this site to Business Plan
Own the profile, publish your feasibility data and reach sponsors directly.
Is something out of date?
Tell us what needs correcting and we'll update this profile.
lock Available to Business plan sites only.